Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial


de Bono J. S. , Oudard S., Ozguroglu M. , Hansen S., Machiels J., Kocak I., ...Daha Fazla

LANCET, cilt.376, sa.9747, ss.1147-1154, 2010 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 376 Konu: 9747
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1016/s0140-6736(10)61389-x
  • Dergi Adı: LANCET
  • Sayfa Sayıları: ss.1147-1154

Özet

Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment.